FATP-4; Fatty acid transport protein 4; Solute carrier family 27 member 4; SLC27A4; ACSVL4; FATP4

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Antigen Affinity Purified

Shipped at 4 degree C. Upon delivery aliquot and store at -20 degree C or -80 degree C. Avoid repeated freeze.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of anti-SLC27A4 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Involved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Appears to be the principal fatty acid transporter in small intestinal enterocytes. Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis. Has acyl-CoA ligase activity for long-chain and very-long-chain fatty acids (VLCFAs). Indirectly inhibits RPE65 via substrate competition and via production of VLCFA derivatives like lignoceroyl-CoA. Prevents light-induced degeneration of rods and cones.

ELISA (EIA), Immunohistochemistry (IHC)

Recommended dilution: IHC:1:20-1:200

Immunohistochemistry of paraffin-embedded human placenta using MBS1493389 at dilution 1:100

26,001 Da

solute carrier family 27 (fatty acid transporter), member 4

long-chain fatty acid transport protein 4

Long-chain fatty acid transport protein 4

ACSVL4; FATP4; FATP-4; Fatty acid transport protein 4??[Similar Products]

S27A4_HUMAN

This gene encodes a member of a family of fatty acid transport proteins, which are involved in translocation of long-chain fatty acids cross the plasma membrane. This protein is expressed at high levels on the apical side of mature enterocytes in the small intestine, and appears to be the principal fatty acid transporter in enterocytes. Clinical studies suggest this gene as a candidate gene for the insulin resistance syndrome. Mutations in this gene have been associated with ichthyosis prematurity syndrome. [provided by RefSeq, Apr 2010]

SLC27A4: Involved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Appears to be the principal fatty acid transporter in small intestinal enterocytes. Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis. Has acyl-CoA ligase activity for long-chain and very-long-chain fatty acids. Defects in SLC27A4 are the cause of ichthyosis prematurity syndrome (IPS). A keratinization disorder characterized by complications in the second trimester of pregnancy resulting from polyhydramnion, with premature birth of a child with thick caseous desquamating epidermis, respiratory complications and transient eosinophilia. After recovery during the first months of life, the symptoms are relatively benign and the patients suffer from a lifelong non-scaly ichthyosis with atopic manifestations. Belongs to the ATP-dependent AMP-binding enzyme family.

Protein type: Transporter, SLC family; Transporter; Membrane protein, integral; Membrane protein, multi-pass; Ligase; EC 6.2.1.-

Chromosomal Location of Human Ortholog: 9q34.11

Cellular Component: brush border membrane; endoplasmic reticulum membrane; integral to membrane; membrane; microvillus; plasma membrane

Molecular Function: fatty acid transporter activity; long-chain-fatty-acid-CoA ligase activity; nucleotide binding; very-long-chain-fatty-acid-CoA ligase activity

Biological Process: fatty acid transport; lipid metabolic process; long-chain fatty acid metabolic process; long-chain fatty acid transport; medium-chain fatty acid transport; response to nutrient; skin development; transmembrane transport; transport; very-long-chain fatty acid catabolic process

Disease: Ichthyosis Prematurity Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.